CN101284823A - 牛蒡苷元前体药物及其制备方法与用途 - Google Patents
牛蒡苷元前体药物及其制备方法与用途 Download PDFInfo
- Publication number
- CN101284823A CN101284823A CNA2007100142835A CN200710014283A CN101284823A CN 101284823 A CN101284823 A CN 101284823A CN A2007100142835 A CNA2007100142835 A CN A2007100142835A CN 200710014283 A CN200710014283 A CN 200710014283A CN 101284823 A CN101284823 A CN 101284823A
- Authority
- CN
- China
- Prior art keywords
- aretigenin
- drug
- preparation
- arctigenin
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NQWVSMVXKMHKTF-UHFFFAOYSA-N L-Arctigenin Natural products C1=C(OC)C(OC)=CC=C1CC1C(CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-UHFFFAOYSA-N 0.000 title claims abstract description 19
- NQWVSMVXKMHKTF-JKSUJKDBSA-N (-)-Arctigenin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O)=CC=2)C(=O)OC1 NQWVSMVXKMHKTF-JKSUJKDBSA-N 0.000 title claims abstract description 15
- YYGRXNOXOVZIKE-UHFFFAOYSA-N Arctigenin Natural products COC1CCC(CC2COC(=O)C2CC3CCC(O)C(C3)OC)CC1OC YYGRXNOXOVZIKE-UHFFFAOYSA-N 0.000 title claims abstract description 15
- OIFFJDGSLVHPCW-UHFFFAOYSA-N Guayarol Natural products COc1ccc(CC2C(Cc3ccc(O)c(O)c3)COC2=O)cc1OC OIFFJDGSLVHPCW-UHFFFAOYSA-N 0.000 title claims abstract description 15
- NWFYESYCEQICQP-UHFFFAOYSA-N methylmatairesinol Natural products C1=C(OC)C(OC)=CC=C1CC1C(=O)OCC1CC1=CC=C(O)C(OC)=C1 NWFYESYCEQICQP-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 28
- 229940002612 prodrug Drugs 0.000 title claims description 25
- 239000000651 prodrug Substances 0.000 title claims description 25
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims abstract description 45
- 239000003814 drug Substances 0.000 claims abstract description 17
- 239000002253 acid Substances 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims abstract description 6
- OBNCKNCVKJNDBV-UHFFFAOYSA-N ethyl butyrate Chemical compound CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims abstract description 3
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229940095064 tartrate Drugs 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 238000005303 weighing Methods 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 208000037487 Endotoxemia Diseases 0.000 claims description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 238000003810 ethyl acetate extraction Methods 0.000 claims description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 3
- 235000011152 sodium sulphate Nutrition 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000008676 import Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000001524 infective effect Effects 0.000 claims description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 150000003890 succinate salts Chemical group 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 230000001986 anti-endotoxic effect Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- -1 sulphonic acid ester Chemical class 0.000 abstract description 3
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 238000005804 alkylation reaction Methods 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- 230000003381 solubilizing effect Effects 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- 108700012359 toxins Proteins 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 235000003130 Arctium lappa Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 240000005528 Arctium lappa Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical compound CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- DJSISFGPUUYILV-ZFORQUDYSA-N scutellarin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-ZFORQUDYSA-N 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- ZITBJWXLODLDRH-UHFFFAOYSA-N (-)-wikstromol Chemical compound C1=C(O)C(OC)=CC(CC2C(C(=O)OC2)(O)CC=2C=C(OC)C(O)=CC=2)=C1 ZITBJWXLODLDRH-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 241000208843 Arctium Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282414 Homo sapiens Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- DJSISFGPUUYILV-UHFFFAOYSA-N UNPD161792 Natural products O1C(C(O)=O)C(O)C(O)C(O)C1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC(O)=CC=1)O2 DJSISFGPUUYILV-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- BPYGTFFYYOWDBC-LOVSFRALSA-N arctiin Natural products COc1ccc(C[C@H]2COC(=O)[C@@H]2Cc3ccc(O[C@@H]4O[C@H](C)[C@@H](O)[C@H](O)[C@H]4O)c(OC)c3)cc1OC BPYGTFFYYOWDBC-LOVSFRALSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- NPLTVGMLNDMOQE-UHFFFAOYSA-N carthamidin Natural products C1=CC(O)=CC=C1C1OC2=CC(O)=C(O)C(O)=C2C(=O)C1 NPLTVGMLNDMOQE-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 1
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000000624 ear auricle Anatomy 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229960005170 moexipril Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 150000002995 phenylpropanoid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229930190376 scutellarin Natural products 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical group OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
参数 | 牛蒡苷元 | 牛蒡苷元琥珀酸单酯 |
Tmax(min) | 40.89±3.34 | 32.58±4.15 |
Cmax(μg/ml) | 43.78±8.52 | 102.62±10.32 |
T1/2β(min) | 248.31±16.52 | 267.46±12.35 |
AUC0-∞(μg.h/ml) | 20503.6±4120.2 | 26410.6±3256.2 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100142835A CN101284823B (zh) | 2007-04-13 | 2007-04-13 | 牛蒡苷元前体药物及其制备方法与用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007100142835A CN101284823B (zh) | 2007-04-13 | 2007-04-13 | 牛蒡苷元前体药物及其制备方法与用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101284823A true CN101284823A (zh) | 2008-10-15 |
CN101284823B CN101284823B (zh) | 2012-05-23 |
Family
ID=40057253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007100142835A Expired - Fee Related CN101284823B (zh) | 2007-04-13 | 2007-04-13 | 牛蒡苷元前体药物及其制备方法与用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101284823B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102863485A (zh) * | 2012-10-16 | 2013-01-09 | 南京农业大学 | 一种牛蒡子苷粗品的纯化方法 |
CN103467417A (zh) * | 2012-06-07 | 2013-12-25 | 中国科学院上海药物研究所 | 牛蒡子苷元碳酰胺衍生物及其制备方法、包含该衍生物的组合物、及其用途 |
CN104529810A (zh) * | 2014-09-02 | 2015-04-22 | 辽宁中医药大学 | 牛蒡苷元衍生物的制备方法及用途 |
JPWO2013146943A1 (ja) * | 2012-03-30 | 2015-12-14 | ロート製薬株式会社 | アルクチゲニン誘導体を含む抗老化剤 |
CN105541764A (zh) * | 2015-12-24 | 2016-05-04 | 吉林农业大学 | 乙酰胆碱酯酶抑制剂木脂内酯组合物及其制备方法与应用 |
CN105541765A (zh) * | 2016-02-03 | 2016-05-04 | 辽宁中医药大学 | 牛蒡苷元氨基酸酯类衍生物及其制备方法和用途 |
CN105796551A (zh) * | 2015-12-24 | 2016-07-27 | 吉林农业大学 | Ace抑制剂木脂内酯组合物及其制备方法与应用 |
CN109053701A (zh) * | 2018-08-03 | 2018-12-21 | 内蒙古民族大学附属医院 | 牛蒡子苷元类化合物、制备方法和用途 |
CN115403571A (zh) * | 2022-09-16 | 2022-11-29 | 延边大学 | 一种牛蒡子苷元衍生物、制备方法及应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1274301C (zh) * | 2003-01-06 | 2006-09-13 | 成都市高新区药工医药生物技术研究所 | α-(3R3-4R4-5R5)-苯甲基-β-(3R3 -4R4-5R5)-苯甲基-γ-丁内酯在制备降血糖药物中的应用 |
-
2007
- 2007-04-13 CN CN2007100142835A patent/CN101284823B/zh not_active Expired - Fee Related
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2013146943A1 (ja) * | 2012-03-30 | 2015-12-14 | ロート製薬株式会社 | アルクチゲニン誘導体を含む抗老化剤 |
CN103467417A (zh) * | 2012-06-07 | 2013-12-25 | 中国科学院上海药物研究所 | 牛蒡子苷元碳酰胺衍生物及其制备方法、包含该衍生物的组合物、及其用途 |
CN103467417B (zh) * | 2012-06-07 | 2015-05-20 | 中国科学院上海药物研究所 | 牛蒡子苷元碳酰胺衍生物及其制备方法、包含该衍生物的组合物、及其用途 |
CN102863485A (zh) * | 2012-10-16 | 2013-01-09 | 南京农业大学 | 一种牛蒡子苷粗品的纯化方法 |
CN102863485B (zh) * | 2012-10-16 | 2015-03-11 | 南京农业大学 | 一种牛蒡子苷粗品的纯化方法 |
CN104529810A (zh) * | 2014-09-02 | 2015-04-22 | 辽宁中医药大学 | 牛蒡苷元衍生物的制备方法及用途 |
CN105541764A (zh) * | 2015-12-24 | 2016-05-04 | 吉林农业大学 | 乙酰胆碱酯酶抑制剂木脂内酯组合物及其制备方法与应用 |
CN105796551A (zh) * | 2015-12-24 | 2016-07-27 | 吉林农业大学 | Ace抑制剂木脂内酯组合物及其制备方法与应用 |
CN105541764B (zh) * | 2015-12-24 | 2017-12-01 | 吉林农业大学 | 乙酰胆碱酯酶抑制剂木脂内酯组合物及其制备方法与应用 |
CN105541765A (zh) * | 2016-02-03 | 2016-05-04 | 辽宁中医药大学 | 牛蒡苷元氨基酸酯类衍生物及其制备方法和用途 |
CN109053701A (zh) * | 2018-08-03 | 2018-12-21 | 内蒙古民族大学附属医院 | 牛蒡子苷元类化合物、制备方法和用途 |
CN109053701B (zh) * | 2018-08-03 | 2020-06-23 | 内蒙古民族大学附属医院 | 牛蒡子苷元类化合物、制备方法和用途 |
CN115403571A (zh) * | 2022-09-16 | 2022-11-29 | 延边大学 | 一种牛蒡子苷元衍生物、制备方法及应用 |
CN115403571B (zh) * | 2022-09-16 | 2024-03-01 | 延边大学 | 一种牛蒡子苷元衍生物、制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101284823B (zh) | 2012-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101284823B (zh) | 牛蒡苷元前体药物及其制备方法与用途 | |
RO120950B1 (ro) | Complex bioactiv de acizi triterpenici, procedeu de obţinere şi produse medicamentoase cu utilizări terapeutice | |
EP2199402A1 (en) | Cycloastragenol monoglucoside, preparation, pharmaceutical composition and application thereof | |
CN1977855A (zh) | 含芒果苷的药用组合物及其制备方法 | |
Wang et al. | Enhancement of oral bioavailability and hypoglycemic activity of liquiritin-loaded precursor liposome | |
CN102772500B (zh) | 具有抗炎作用的热淋清颗粒原料头花蓼提取物 | |
WO2023065376A1 (zh) | 一种包含落新妇苷和/或其异构体的组合物在制备治疗银屑病的药物中的用途 | |
WO2005003145A1 (en) | Shanzhuyu extract and uses thereof | |
CN101036644A (zh) | 含牛蒡子苷元的药用组合物及其制备方法 | |
CN101781355B (zh) | 柠檬苦素的制备方法及组合物和其应用 | |
Yang et al. | Can aloin develop to medicines or healthcare products? | |
CN1931868A (zh) | 玄参总苯素苷及其制备方法和应用 | |
CN106432385B (zh) | 一种高纯度灯盏花素提取物及制剂的制备方法及用途 | |
CN102772497B (zh) | 热淋清颗粒药材醇提有效部位及其制备方法 | |
WO2020156330A1 (zh) | 一种用于治疗人恶性脑胶质瘤或黑色素瘤的番荔枝种子提取物及其制备方法和应用 | |
US20210032374A1 (en) | Isolated saposhnikovia divaricata polysaccharide and use thereof | |
CN103816147B (zh) | 藤黄酸、新藤黄酸及其组合物的医药用途 | |
CN107056869A (zh) | 一种睡茄交酯类化合物及提取方法及应用 | |
CN112807337B (zh) | 一种坎巴嘎布提取物及其制备方法和应用 | |
CN102942610A (zh) | 人参皂苷m1正丁酸酯的制备及其抗糖尿病医药用途 | |
CN101073598B (zh) | 一种治疗心脑血管病的药物组合物及其制剂 | |
CN108125995B (zh) | 一种银杏叶黄酮提取物及其应用 | |
CN108129437B (zh) | 一种黄酮化合物及其制备方法与应用 | |
JP2021512998A (ja) | 分離された白茅根多糖及びその用途 | |
CN113861302B (zh) | 一种山茱萸多糖组分及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Junfeng Document name: Notification of an Office Action |
|
DD01 | Delivery of document by public notice |
Addressee: Liu Junfeng Document name: Notification to Go Through Formalities of Registration |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Yantai Target Drug Research Co.,Ltd. Person in charge of patentsThe principal of patent Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Yantai Target Drug Research Co.,Ltd. Person in charge of patentsThe principal of patent Document name: Notice of termination of patent right |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120523 |